{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-001630","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.112519+00:00","generated_at":"2026-05-27T14:20:13.008663+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Genprex doses first patient in Phase 2 expansion of Acclaim-3 trial for Reqorsa + Tecentriq in ES-SCLC","bullets":["Phase 2 expansion will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week progression-free survival rate.","Recommended Phase 2 dose of Reqorsa set at 0.12 mg/kg (highest Phase 1 dose), no dose-limiting toxicities observed.","Interim analysis planned after first 25 patients reach 18 weeks of follow-up; enrollment of initial 25 expected in H2 2025.","Acclaim-3 holds FDA Fast Track and Orphan Drug Designations for this extensive-stage small cell lung cancer indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-001630","json":"https://secwatch.observer/filing/0001437749-25-001630.json","markdown":"https://secwatch.observer/filing/0001437749-25-001630.md","text":"https://secwatch.observer/filing/0001437749-25-001630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925001630/0001437749-25-001630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925001630/gnpx20241220_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T14:20:13.008663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}